CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...